Point Of Care Coagulation Testing Devices Market Size
| Study Period | 2019 - 2029 |
| Market Size (2024) | USD 1.56 Billion |
| Market Size (2029) | USD 2.07 Billion |
| CAGR (2024 - 2029) | 5.74 % |
| Fastest Growing Market | Asia Pacific |
| Largest Market | North America |
| Market Concentration | High |
Major Players
*Disclaimer: Major Players sorted in no particular order |
Point Of Care Coagulation Testing Devices Market Analysis
The Point Of Care Coagulation Testing Devices Market size is estimated at USD 1.56 billion in 2024, and is expected to reach USD 2.07 billion by 2029, growing at a CAGR of 5.74% during the forecast period (2024-2029).
Point of care coagulation testing devices are used to measure the clotting time of patients with bleeding disorders. The demand for these devices is attributed to the increasing prevalence of bleeding disorders. According to a study published by the American Society of Hematology in November 2023, among a 1,019-patient population, 235 patients, which is 23%, were diagnosed with bleeding disorders, of which 37% were women. In addition, as per the World Federation of Hemophilia's December 2022 update, hemophilia is considered a rare disease, and 21 in 100,000 males have hemophilia A, whereas 4 in 100,000 males have hemophilia B. The increase in the patient population with bleeding disorders is surging the demand for routine anticoagulation monitoring, which is one of the significant factors influencing market growth. An increase in demand for coagulation tests is expected to boost the demand for point of care coagulation testing devices, thereby driving market growth.
Furthermore, the benefits offered by these devices over conventional testing fuel the market growth. The turnaround is fast compared to laboratory-based testing, reducing the treatment time. At the point of care, these devices offer real-time visual displays of clots and reduce non-evidence-based transfusion.
Moreover, technologically advanced products introduced by market players provide rapid assessment and high sensitivity toward specific blood components to determine the overall coagulation status of patients. According to a study published by the Saudia Journal of Anesthesia in March 2023, the point of care thromboelastography (TEG) and thromboelastometry (ROTEM) reduced morbidity rates among patients with primary postpartum hemorrhage. Moreover, the utility of TEG and ROTEM warranted long-term survival and cost-benefit in patients. Hence, such technological advancements in the devices are projected to drive market growth over the next five years.
In addition, governments globally prioritize early detection of blood-related diseases to reduce the healthcare burden, leading to a surge in initiatives, including funding, policies, and awareness campaigns. For instance, in February 2024, the Red Tie Campaign was organized by the National Bleeding Disorders Foundation in the United States to advance the fight against inheritable bleeding disorders by raising funds for research, education, and advocacy initiatives. Thus, such initiatives to improve the diagnosis rate for bleeding disorders are anticipated to surge the demand for point of care coagulation testing devices, leading to market growth.
However, factors such as the high cost of point of care coagulation testing devices, lack of skilled professionals, and low accessibility in low-income countries restrain the market growth.
Point Of Care Coagulation Testing Devices Market Trends
The Instruments Segment is Expected to Dominate the Market Between 2024 and 2029
Instruments such as monitors and analyzers evaluate the coagulation status of patients with blood-related disorders. The increasing cases of coagulation disorders like hemophilia, Von Willibrand, liver disease-associated bleeding, and vitamin K deficiency bleeding are projected to grow in the upcoming years. According to the World Federation of Hemophilia 2023 Report, 11,245 patients were identified with Hemophilia A, 2,050 with Hemophilia B, and 48 with unknown bleeding disorders from 13,343 enrolled patients across 44 countries. Hence, such instances suggest the increasing need for coagulation testing devices, thereby projected to drive the segmental growth between 2024 and 2029.
Moreover, the introduction of technologically advanced products such as rotational thromboelastometry (ROTEM) and thromboelastography (TEG) provides a more comprehensive evaluation of the whole blood’s propensity to form a clot. TEG and ROTEM have several advantages over traditional coagulation tests and are becoming increasingly important tools in managing patients with complex coagulation disorders. An article published by OpenAnesthesia in March 2024 stated that traditional coagulation tests provide a static outline of clotting ability, whereas viscoelastic tests such as TEG/ROTEM provide a dynamic picture of the clotting process and potential abnormalities.
The efficiency of technologically advanced products over traditional ones is anticipated to increase the adoption of coagulation testing devices among the patient population. Additionally, the ability of instruments to provide rapid assessment with high specificity for various blood components is expected to dominate the market in the upcoming years.
North America is Expected to Dominate the Point of Care Coagulation Testing Devices Market
North America is expected to dominate the market due to factors such as an increasing patient population with bleeding disorders, developed healthcare infrastructure, new product launches, and established players in the region. According to the Centers for Disease Control and Prevention, around 1.6 million females in the United States have bleeding disorders and are unaware of their condition. The bleeding disorders community includes patients living with von Willibrand disease, hemophilia, platelet disorders, and other rare conditions.
Moreover, as per the data published by the Canadian Hemophilia Society, in November 2023, around 300,000 Canadians carry an inherited bleeding disorder gene, of which only 10,000 people are registered in the Canadian network of inherited bleeding disorder comprehensive care clinics. Such blood-related diseases are anticipated to boost the adoption of point-of-care coagulation testing devices, thus influencing market growth in the region.
Furthermore, the market is driven by increased government initiatives, education programs, and awareness campaigns toward bleeding disorders. For instance, in October 2023, the World Federation of Hemophilia introduced Path to Access Care and Treatment (PACT), a multidisciplinary program in Mexico. A five-year outreach and diagnosis program aimed to improve and increase access to sustainable care for people with bleeding disorders. Hence, these initiatives increase the adoption of coagulation testing devices, thus contributing to market growth.
Additionally, several prominent players in the market are focused on expanding their geographical presence, which in turn is projected to create numerous growth opportunities for the market, thereby influencing market growth. For instance, in August 2023, Sysmex Corporation renewed its global partnership with F. Hoffmann-La Roche Ltd on hematology solutions. F. Hoffmann-La Roche Ltd will continue to offer Sysmex's hematology products, complementing their total laboratory solutions portfolio. Such strategic initiatives by key players to increase access to routine hematology diagnostic solutions are expected to drive the market growth.
Therefore, owing to the abovementioned factors, the market is anticipated to grow in North America.
Point Of Care Coagulation Testing Devices Industry Overview
The point of care coagulation testing devices market is consolidated due to the dominance of key players operating globally and regionally. The competitive landscape includes an analysis of a few international companies with substantial market shares, including F. Hoffmann-La Roche Ltd, Siemens Healthineers AG, and Abbott.
Point Of Care Coagulation Testing Devices Market Leaders
-
F. Hoffmann-La Roche Ltd
-
Siemens Healthineers AG
-
Abbott
-
Werfen
-
HemoSonics, LLC.
*Disclaimer: Major Players sorted in no particular order
Point Of Care Coagulation Testing Devices Market News
- In February 2024, F. Hoffmann-La Roche Ltd introduced three new coagulation tests in countries accepting CE marks to meet the rise in demand for oral anticoagulants across Europe.
- In April 2024, Siemens Healthineers AG and Sysmex Corporation independently initiated the distribution of Siemens Hemostasis testing solutions in Europe and the US laboratories.
Point Of Care Coagulation Testing Devices Market Report - Table of Contents
1. INTRODUCTION
1.1 Study Assumptions and Market Definition
1.2 Scope of the Study
2. RESEARCH METHODOLOGY
3. EXECUTIVE SUMMARY
4. MARKET DYNAMICS
4.1 Market Overview
4.2 Market Drivers
4.2.1 Increasing Patient Population with Bleeding Disorders
4.2.2 Benefits Offered Over Conventional Testing
4.3 Market Restraints
4.3.1 Expensive Compared to Conventional Testing
4.4 Porter's Five Forces Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry
5. MARKET SEGMENTATION (Market Size by Value - USD)
5.1 By Type
5.1.1 Instruments
5.1.2 Consumables
5.2 By Test Type
5.2.1 Anticoagulation Testing
5.2.2 Platelet Function Test
5.2.3 Viscoelastic Testing
5.2.4 Others
5.3 By End User
5.3.1 Hospitals
5.3.2 Diagnostic Centers
5.3.3 Others
5.4 Geography
5.4.1 North America
5.4.1.1 United States
5.4.1.2 Canada
5.4.1.3 Mexico
5.4.2 Europe
5.4.2.1 Germany
5.4.2.2 United Kingdom
5.4.2.3 France
5.4.2.4 Italy
5.4.2.5 Spain
5.4.2.6 Rest of Europe
5.4.3 Asia-Pacific
5.4.3.1 China
5.4.3.2 Japan
5.4.3.3 India
5.4.3.4 Australia
5.4.3.5 South Korea
5.4.3.6 Rest of Asia-Pacific
5.4.4 Middle East and Africa
5.4.4.1 GCC
5.4.4.2 South Africa
5.4.4.3 Rest of Middle East and Africa
5.4.5 South America
5.4.5.1 Brazil
5.4.5.2 Argentina
5.4.5.3 Rest of South America
6. COMPETITIVE LANDSCAPE
6.1 Company Profiles
6.1.1 F. Hoffmann-La Roche Ltd
6.1.2 Siemens Healthineers AG
6.1.3 Abbott
6.1.4 Werfen
6.1.5 Koninklijke Philips NV
6.1.6 Helena Laboratories Corporation
6.1.7 HemoSonics LLC
6.1.8 Haemonetics Corporation
6.1.9 Medtronic
6.1.10 Shenzhen Micropoint Biotechnologies Co. Ltd
7. MARKET OPPORTUNITIES AND FUTURE TRENDS
Point Of Care Coagulation Testing Devices Industry Segmentation
Point of care coagulation testing devices perform multiple coagulation tests and provide insights related to the patient's clotting status. These tests are essential for evaluating and monitoring patients with bleeding disorders. These devices offer timely results by reducing turnaround time and decreasing treatment time.
The point of care coagulation testing devices market is segmented into type, test type, end-user, and geography. By type, the market is segmented into instruments and consumables. By test type, the market is segmented into anticoagulation testing, platelet function test, viscoelastic testing, and others. By end-user, the market is segmented into hospitals, diagnostic centers, and other end-users. By geography, the market is segmented into North America, Europe, Asia-Pacific, South America, and Middle East and Africa. The report also offers the market size and forecasts for 17 countries across the region. The report offers the value (in USD) for the above segments.
| By Type | |
| Instruments | |
| Consumables |
| By Test Type | |
| Anticoagulation Testing | |
| Platelet Function Test | |
| Viscoelastic Testing | |
| Others |
| By End User | |
| Hospitals | |
| Diagnostic Centers | |
| Others |
| Geography | ||||||||
| ||||||||
| ||||||||
| ||||||||
| ||||||||
|
Point Of Care Coagulation Testing Devices Market Research FAQs
How big is the Point Of Care Coagulation Testing Devices Market?
The Point Of Care Coagulation Testing Devices Market size is expected to reach USD 1.56 billion in 2024 and grow at a CAGR of 5.74% to reach USD 2.07 billion by 2029.
What is the current Point Of Care Coagulation Testing Devices Market size?
In 2024, the Point Of Care Coagulation Testing Devices Market size is expected to reach USD 1.56 billion.
Who are the key players in Point Of Care Coagulation Testing Devices Market?
F. Hoffmann-La Roche Ltd, Siemens Healthineers AG, Abbott, Werfen and HemoSonics, LLC. are the major companies operating in the Point Of Care Coagulation Testing Devices Market.
Which is the fastest growing region in Point Of Care Coagulation Testing Devices Market?
Asia Pacific is estimated to grow at the highest CAGR over the forecast period (2024-2029).
Which region has the biggest share in Point Of Care Coagulation Testing Devices Market?
In 2024, the North America accounts for the largest market share in Point Of Care Coagulation Testing Devices Market.
What years does this Point Of Care Coagulation Testing Devices Market cover, and what was the market size in 2023?
In 2023, the Point Of Care Coagulation Testing Devices Market size was estimated at USD 1.47 billion. The report covers the Point Of Care Coagulation Testing Devices Market historical market size for years: 2019, 2020, 2021, 2022 and 2023. The report also forecasts the Point Of Care Coagulation Testing Devices Market size for years: 2024, 2025, 2026, 2027, 2028 and 2029.
Point Of Care Coagulation Testing Devices Industry Report
Statistics for the 2024 Point Of Care Coagulation Testing Devices market share, size and revenue growth rate, created by Mordor Intelligence™ Industry Reports. Point Of Care Coagulation Testing Devices analysis includes a market forecast outlook for 2024 to 2029 and historical overview. Get a sample of this industry analysis as a free report PDF download.
